Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/10537
Title: The frequency of EGFR and KRAS mutations in the Turkish population with non-small cell lung cancer and their response to erlotinib therapy
Authors: Demiray, Aydın
Yaren, Arzu
Karagenc, Nedim
Bir, Ferda
Demiray, Atike Gökçen
Er, K.
Tokgun, Onur
Keywords: Epidermal growth factor receptor (EGFR)
Erlotinib therapy
Kirsten ras sarcoma (KRAS)
Non-small cell lung cancer (NSCLC)
DNA
epidermal growth factor receptor
erlotinib
K ras protein
adult
aged
Article
cancer genetics
cancer patient
cancer survival
DNA determination
female
gene frequency
human
lung adenocarcinoma
major clinical study
male
middle aged
mutational analysis
non small cell lung cancer
overall survival
point mutation
polymerase chain reaction
population genetics
progression free survival
pyrosequencing
smoking habit
squamous cell lung carcinoma
survival rate
treatment response
Turk (people)
Publisher: Sciendo
Abstract: In this study, profiles of epidermal growth factor receptor (EGFR) and Kirsten ras sarcoma (KRAS) mutations and response to erlotinib therapy have been investigated in patients with non-small cell lung cancer (NSCLC). DNA from 300 patients with NSCLC was extracted from paraf-fin-embedded tissues. After the extracted DNA was sequenced by pyrosequencing method, a total of 97 (32.0%) patients out of 300 were detected to carry an EGFR mutation and 75 (25.0%) patients out of 300 carried a KRAS mutation; 20 (6.6%) patients were detected to carry both of EGFR and KRAS mutations. The EGFR mutations were found to be statistically significant in female patients (48.0 women vs. 28.0% men, non smokers (49.0 vs. 26.0%) and adenocarcinoma (37.8 vs. squamous 26.8%). The overall rate of survival in patients receiving erlotinib therapy than in patients who did not. In patients without the KRAS mutation, the median overall survival rate was 161 ± 30 weeks with erlotinib therapy and 90 ± 13 weeks in patients without erlotinib therapy. In patients having KRAS mutation, the median overall survival was 98 ± 16 weeks with erlotinib therapy and 34 ± 16 weeks with no erlotinib therapy. In our study, we once again demonstrated that the presence of these mutations affected response to erlotinib therapy. The KRAS mutations negatively affected survival rate with and without erlotinib therapy. © 2018 Demiray A, Yaren A, Karagenç N, Bir F, Demiray AG, Karagür ER, Tokgün O, Elmas L, Akça H, published by Sciendo.
URI: https://hdl.handle.net/11499/10537
https://doi.org/10.2478/bjmg-2018-0022
ISSN: 1311-0160
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
THE FREQUENCY OF EGFR.pdf475 kBAdobe PDFView/Open
Show full item record



CORE Recommender

SCOPUSTM   
Citations

11
checked on Oct 13, 2024

WEB OF SCIENCETM
Citations

9
checked on Dec 18, 2024

Page view(s)

66
checked on Aug 24, 2024

Download(s)

30
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.